-
| Exchange | NASDAQ |
|---|---|
| CurrencyCode | USD |
| ISIN | US0080642061 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Beta | nan |
|---|---|
| Market Cap | 280M |
| PE Ratio | None |
| Dividend Yield | 0.0% |
| Target Price | 16.6667 |
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. The company develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. It also develops JADE201 and JADE-003, which are in preclinical development stage. The company has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. was founded in 2024 and is headquartered in Waltham, Massachusetts.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for JBIO using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025